drugset / Trial / NCT06946485
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
Phase 0
Recruiting
15 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NaSingle-groupOpen-labelTreatment
Summary
This investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.
Timeline
- Start
- 2025-04-02
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CHT101 | Cell therapy | — | — |